News | January 23, 2026
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Subscribe To Our Newsletter & Stay Updated
